Home › Compare › OSOPF vs ABBV
OSOPF yields 2682.25% · ABBV yields 3.06%● Live data
📍 OSOPF pulled ahead of the other in Year 1
Combined, OSOPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of OSOPF + ABBV for your $10,000?
Osotspa Public Company Limited, together with its subsidiaries manufactures and distributes energy drinks and personal care products worldwide. The company operates in three segments: Beverage, Personal Care, and Others. It offers energy drinks under the M-150, Lipovitan-D, Chalarm, Som in-Sum, White Shark, Shark Energy Drink, and M-Storm brand names; ready-to drink coffee under the M-Presso name; sport drinks under the M-Electrolyte brand; and functional drinks under the Peptein, Peptein Gold, C-Vitt, Calpis Lacto, and Slimma brands. The company also provides baby care products under the Babi Mild brand name; male grooming products under the Exit brand; women beauty care products under the Twelve Plus, Plantstory, Ole Strwaberry, PROhada, and OTG brands; healthcare products under the KRISNAKLAN, Utaitip, Tamjai, YATHAD 4, Yixin, and BANNER brands; and confectionery products under the Botan and Ole brand names. In addition, it provides marketing and property rental services; manufactures and distributes glass, and beverage concentrates and premixes; and distributes food, beverages, and cullet products. Further, the company engages in the import, retail, and wholesale of beverages; investing in other companies; provision of research and development services; electronic commerce business; and education and sale of herbal products. Additionally, it obtains licensing fee for use of trademark, as well as offers manufacturing and distribution services. Osotspa Public Company Limited was founded in 1891 and is based in Bangkok, Thailand.
Full OSOPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.